TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - March 31, 2016) - VAXIL BIO LTD.(TSX VENTURE: VXL), an Israeli biotechnology company specializing in cancer immunotherapy, is very pleased to report that it has received a Notice of Allowance from the Canadian Intellectual Property Office (CIPO) for Canadian Patent Application No. 2,665,816 entitled "Antigen Specific Multi Epitope Vaccines." The patent would make Vaxil the Canadian leader in regard to utilizing MUC1 signal peptide domains as cancer immunotherapy treatments.
As opposed to many other cancer vaccines targeting entire cancer antigens, Vaxil has developed its proprietary immunotherapy platform for producing cancer vaccines relevant to specific signal peptide domains within the cancer antigen. This patent allowance protects Vaxil's ownership of all signal peptides of the MUC1 cancer target. MUC1 is known to be a highly important cancer target, given its therapeutic function, immunogencitiy, and wide presence in many cancer types. Vaxil will now be protected in Canada for the development of any signal peptide domain of the MUC1 cancer antigen. Vaxil's lead product, the Immucin™ cancer vaccine, represents one such promising variation of MUC1's signal peptide: the 21-mer peptide domain.
ImMucin™, is an immunotherapeutic treatment which educates a cancer patient's immune system, particularly T-cells and antibodies, to attack cancer cells via a specific domain, termed signal peptide, of the MUC1 cancer antigen. In a Phase-I/II trial which included 15 multiple myeloma patients, 100% of patients demonstrated robust immune responses, including both T-Cells and B-Cells.This signal peptide domain of the MUC1 cancer target, bears significant advantages as an immunotherapeutic agent, including its presence on approximately 90% of all cancer types.
Read more: http://www.marketwired.com/press-release/vaxil-receives-canadian-notice-patent-allowance-its-lead-immunotherapy-platform-including-tsx-venture-vxl-2110683.htm